Toggle Health Problems and D

Kidney Cancer 4X more likely if poor Vitamin D Binding Protein (5X in previous study) – Oct 2019

Vitamin D Binding Protein and Risk of Renal Cell Carcinoma in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO).

Int J Cancer. 2019 Oct 29. doi: 10.1002/ijc.32758
Kratzer TB1, Weinstein SJ2, Albanes D2, Mondul AM1.
1 Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI.
2 Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD.

Vitamin D Binding Protein category listing has 176 items and the following introduction

Vitamin D Binding Protein (GC) gene can decrease the bio-available Vitamin D that can get to cells,

  • GC is not the only such gene - there are 3 others, all invisible to standard Vitamin D tests
  • The bio-available calculation does not notice the effect of GC, CYP27B1, CYP24A1, and VDR
  • The actual D getting to the cells is a function of measured D and all 4 genes
  • There is >2X increase in 8+ health problems if have poor VDBP (GC)
  • It appears that VDBP only blocks oral vitamin D,

Vitamin D Binding Protein has a list of health problems

Health Problem
11 XPreeclampsia
6.5XT1D in SA Blacks
6 XFood Allergy
4 X, 5XKidney Cancer
4 XPoor Response to Oral Vitamin D
3 XEar infection
2.8 X MS
2 X Colorectal Cancer
2 XProstate Cancer -in those with dark skins
1.3 XInfertility

Our group has conducted two previous studies on the association between vitamin D binding protein (DBP) and renal cell carcinoma (RCC), the most common form of kidney cancer, finding strong inverse associations. We undertook the current analysis to replicate our findings in a different study population that included women and non-smokers. We conducted a nested case-control study in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO). Cases (n=323) were matched 1:1 to controls on age (+/- 1 year), race, date of blood collection (+/- 30 days) and sex. We performed conditional logistic regression to estimate the odds ratios and 95% confidence intervals for the association between quartiles of circulating DBP and risk of RCC.
We observed a statistically significant positive association between DBP and RCC that persisted after adjustment for history of diabetes, history of hypertension, family history of renal cancer, body mass index (BMI), and smoking status (mv-adj Q4 vs. Q1 OR=4.1, 95% CI=2.2-7.8; p-trend <0.0001).
These findings were similar when we restricted to cases with at least two years of follow-up and no major weight loss, suggesting that our findings are not due to reverse causality. In the present study, those with higher serum concentrations of DBP were at increased risk of RCC, in contrast to previously published findings. Further research is necessary to determine the true association between DBP and risk of RCC, and whether different DBP phenotypes may have different associations with risk of RCC.